Asper Biotech has updated its Ashkenazi Jewish Diseases Test to include mutations in the BRCA1, BRCA2, and LCA5 genes that are common in the Ashkenazi Jewish population. Asper's test now detects up to 112 variants in 27 genes. The test is run using arrayed primer extension and enables the analysis of the most common mutations associated with severe disorders in the Ashkenazi Jewish population, such as cystic fibrosis, Tay-Sachs disease, maple syrup urine disease, and others.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.